Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Federal Trade Commission

Generated: September 18, 2019

DrugPatentWatch Database Preview

Patent: 8,778,339

  Try a free trial

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,778,339
Title:Combination of Fc.gamma.RIIB-specific antibodies and CD20-specific antibodies and methods of use thereof
Abstract: The present invention relates to methods of treatment, prevention, management or amelioration of one or more symptoms of diseases or disorders associated with CD20 expression that encompass administration of a combination of: (A) one or more antibodies that specifically bind Fc.gamma.RIIB, particularly human Fc.gamma.RIIB, with greater affinity than said antibodies bind Fc.gamma.RIIA, and (B) one or more antibodies that specifically bind to CD20. Such methods include methods of treating, preventing, managing or ameliorating one or more symptoms of a B cell related disease or disorder or an inflammatory disorder. The invention also provides pharmaceutical compositions comprising an anti-Fc.gamma.RIIB antibody and an anti-CD20 antibody.
Inventor(s): Tuaillon; Nadine (Gettysburg, PA), Rankin; Christopher (Cabin John, MD)
Assignee: MacroGenics, Inc. (Rockville, MD)
Application Number:12/342,305
Patent Claims:see list of patent claims

Details for Patent 8,778,339

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Try a Free Trial MacroGenics, Inc. (Rockville, MD) 2026-06-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.